Uric acid levels are elevated in people with cardiovascular disease, and high levels are associated with vascular dysfunction and cardiovascular mortality.13, 14, 15 Inhibiting myeloperoxidase may therefore provide therapeutic benefit in patients with cardiovascular diseases, by limiting impairment of vascular function and the subsequent development of fibrosis. Here, MPO is linked to cardiovascular disorder.